Curewize is a leader in the field of personalized medicine, diagnostics and predictive medicine. The Company's goal is to improve the survival rate and overall health outcome of cancer patients.  Our proprietary platform technology measures microRNA (miRNA) profiles in patients’ biofluids. MiRNAs control gene activity, and are considered superior biomarkers for diagnosis and personalized treatment decisions due to their direct link to cancer mechanisms and stability in human biofluid samples. The company’s initial product is ProALL, a groundbreaking lab test for deciding on the intensity of treatment of acute lymphoblastic leukemia (ALL) patients.  Lead Product  The ProALL bone marrow (BM) lab test is our lead product, measuring the level of three miRNA molecules in samples taken a...

Read More

what we do

EXPERTISE

Curewize is positioned with an accurate, industrial standard proprietary platform technology. Our mangement are experts in the development and commerc

Read More

TRANSFER

Translate and transfer microRNA biomaker lab tests to clincial practice. Connecting groundbreaking academic discoveries to Curewize platform technolgy

Read More

PERSONALIZE

Personalized medicine seperates cancer patients into different groups for precise treatment decisions and tailored medicine. Personalized medicine is

Read More

CREATE

Create tools based on microRNA biomarkers  for tailoring cancer patients optimal treatment. Curewize is industrializing cancer-specific prognosti

Read More

What Healthcare Professionals Have to Say

latest news

European Hematology Association Congress

Date : 28.05.2018

Curewize is proud to be presenting results at the 23rd EHA congress in Sweden, June 16 2018: 1.  ProALLBM clinical trial on AIEOP B-ALL cohort  and 2. miR-451 tumor suppresor study. 

Read More

Successful Completion of ProALL-BM Clini

Date : 03.04.2018

Curewize successfully completed the clinical trial of its lead product ProALLBM on a cohort of acute lymphoblastic leukemia (ALL) patients from a European National Registry Study. ProALLBM is being produced for deciding on ALL patients risk-based treatment group, varying from standard to i ...

Read More

Patent Allowance by Israel Patent Office

Date : 24.01.2017

Curewize Health Ltd., a diagnostic company focused on the development of proprietary diagnostics for the treatment of Acute Lymphoblastic Leukemia (ALL), announced that the Israeli Patent Authority has indicated on January 24, 2017 that it intends to grant a patent relating to Curewize’s ProAL ...

Read More